


IPW

DOCKET NO.: ISIS-5325

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Charles Allerson, et al.

Confirmation No.: 5641

Application No.: 10/701,007

Group Art Unit: 1645

Filing Date: November 4, 2003

Examiner: Not Yet Assigned

For: **COMPOSITIONS COMPRISING ALTERNATING 2'-MODIFIED
NUCLEOSIDES FOR USE IN GENE MODULATIONS**

EXPRESS MAIL LABEL NO: EV325727340US

DATE OF DEPOSIT: *January 26, 2005*

EV325727340US

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- ☒ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or

before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

- ☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached; or

☐ The fee of \$180.00 as set forth in § 1.17(p) is attached.

- ☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).

- ☒ Copies of reference numbers **117 – 121 and 130** listed on the attached Form PTO-1449 are enclosed herewith.

- ☒ Copies of reference numbers **122 - 129** on the attached Form PTO 1449 are not required to be submitted pursuant to 37 CFR § 1.98(a)(2)(i).

☐ Copies of references - are not being submitted because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application number , filed for which a claim for priority under 35 U.S.C. § 120 has been made in the instant application.

- ☐ The relevance of those listed references which are not in the English language is as follows:

DOCKET NO.: ISIS-5325


- 3 -

PATENT

There are no listed references which are not in the English language.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.


Date: January 25, 2005



John A. Harrelson, Jr.
Registration No. 42,637

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

© 2005 WW



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. ISIS-5325	Application No. 10/701,007
		Applicant Charles Allerson, et al.	
		Filing Date November 4, 2003	Group 1645
		Confirmation No. 5641	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
**	117	Bass, B.L., "Double-stranded RNA as a template for gene silencing," <i>Cell</i> , 2000 , 101, 235-238	
****	118	Elbashir, S.M., et al., "RNA interference is mediated by 21- and 22-nucleotide RNAs," <i>Genes & Development</i> , 2001 , 15, 188-200	
**	119	Lipardi, C., et al., "RNAi as random degradative PCR: siRNA primers convert mRNA into dsRNAs that are degraded to generate new siRNAs," <i>Cell</i> , 2001 , 107, 297-307	
****	120	Paddison, P.J., et al., "Stable suppression of gene expression by RNAi in mammalian cells," <i>PNAS</i> , 2002 , 99(3), 1443-1448	
****	121	Wang, J., et al., "Cyclohexene nucleic acids (CeNA): serum stable oligonucleotides that activate RNase H and increase duplex stability with complementary RNA," <i>J. Am. Chem. Soc.</i> , 2000 , 122, 8595-8602	
EXAMINER		DATE CONSIDERED	

* Cited on PCT International Search Report dated January 6, 2005 (PCT/US03/35071).

** Cited on PCT International Search Report dated January 10, 2005 (PCT/US03/35067).

***Cited on PCT International Search Report dated January 4, 2005 (PCT/US03/35146).

****Cited on PCT International Search Report dated January 7, 2005 (PCT/US03/35061).



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. ISIS-5325	Application No. 10/701,007
	Applicant Charles Allerson, et al.	
	Filing Date November 4, 2003	Group 1645
	Confirmation No. 5641	

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
****	122	5,607,922	03/04/97	De Clercq, et al.	514	43
****	123	5,681,940	10/28/97	Wang, et al.	536	22.1
***	124	6,150,510	11/21/00	Seela, et al.	536	22.1
***	125	6,294,522 B1	09/25/01	Zablocki, et al.	541	46
****	126	6,329,346 B1	12/11/01	Muhlegger, et al.	514	44
***	127	2002/0160393 A1	10/31/02	Symonds, et al.	435	6
*	128	2003/0143732 A1	07/31/03	Fosnaugh, et al.	435	325
*	129	2003/0206887 A1	11/06/03	Morrissey, et al.	424	93.2

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
**	130	WO 03/072705 A2	09/04/03	PCT		

EXAMINER

DATE CONSIDERED

- * Cited on PCT International Search Report dated January 6, 2005 (PCT/US03/35071).
- ** Cited on PCT International Search Report dated January 10, 2005 (PCT/US03/35067).
- ***Cited on PCT International Search Report dated January 4, 2005 (PCT/US03/35146).
- ****Cited on PCT International Search Report dated January 7, 2005 (PCT/US03/35061).